Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.59 |
| ▸ | CTSB | P07858 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | HLA-DRB1 | P01911 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10802556 | 0.89 | CTSL (0.70) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7266645 | 0.86 | CAPN1 (0.62) | CTSLCTSBCTSK | |
| SCHEMBL6020588 | 0.86 | CTSL (0.60) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL10964365 | 0.85 | MMP8 (0.56) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL996293 | 0.85 | L3MBTL1 (0.58) | CTSLCTSBCTSSCTSKMMP8 | |
| SCHEMBL996291 | 0.85 | L3MBTL1 (0.58) | CTSLCTSBCTSSCTSKMMP8 | |
| SCHEMBL3769914 | 0.85 | L3MBTL1 (0.58) | CTSLCTSBCTSSCTSKMMP8 | |
| SCHEMBL26690545 | 0.85 | MMP9 (0.56) | CTSSCTSKMMP1MMP8ALDH1A1 | |
| SCHEMBL26690546 | 0.85 | MMP9 (0.56) | CTSSCTSKMMP1MMP8ALDH1A1 | |
| SCHEMBL8244008 | 0.84 | ALDH1A1 (0.59) | CTSLCTSBCTSSCTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872919-B2 | Prodrugs for selective anticancer therapy | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160184459-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-06-30 | — | — | US | disclosed |
| US-20150224208-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184459-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | OR10J3, CCR3, GPR3 | CTSL 4560/4885CTSB 4526/4885CTSS 4685/4885 |
| US-20150224208-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | NR4A3, ORC3, NTSR1 | CTSL 2728/4885CTSB 3329/4885CTSS 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.